DDInter1585 DDInter1397
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfinpyrazone
Sulfinpyrazone {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Paroxetine
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) downregulates {v} (Gene) LIPA
LIPA {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminocaproic acid
Aminocaproic acid {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaprozin {u} (Compound) causes {v} (Side Effect) Anaphylactoid reaction
Anaphylactoid reaction {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) binds {v} (Gene) FADS1
FADS1 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminocaproic acid
Aminocaproic acid {u} (Compound) downregulates {v} (Gene) PRR7
PRR7 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Citalopram
Citalopram {u} (Compound) palliates {v} (Disease) panic disorder
panic disorder {u} (Disease) is palliated by {v} (Compound) Paroxetine
Reteplase {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Fondaparinux {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Reteplase {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Paroxetine
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Paroxetine (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) downregulates LIPA (Gene) and LIPA (Gene) is upregulated by Paroxetine (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Aminocaproic acid and Aminocaproic acid (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is downregulated by Paroxetine (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by Paroxetine (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Paroxetine (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) binds FADS1 (Gene) and FADS1 (Gene) is upregulated by Paroxetine (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Aminocaproic acid and Aminocaproic acid (Compound) downregulates PRR7 (Gene) and PRR7 (Gene) is downregulated by Paroxetine (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) palliates panic disorder (Disease) and panic disorder (Disease) is palliated by Paroxetine (Compound)
Reteplase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Paroxetine (Compound)
Reteplase may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Paroxetine (Compound)